
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
Paris-Basic research in erectile dysfunction therapy is being hamperedby the attitude of some funding bodies that phosphodiesterase type-5 inhibitorsalone have solved all problems, according to a special committee convenedat the 2nd International Consultation on Erectile and Sexual Dysfunctionshere.





